reason report
prvb earn updat outperform clinic
bottom line no-cal print result model updat
secur see look ahead pre-bla meet
fda expect late earli expect complet
first cgmp produc lot teplizumab regulatori purpos
also expect top-lin result phase princ trial
announc set clock
janssen op decis recal drug due high
expect janssen recal see princ
readout margin impact overal pt howev
janssen recal import implic prvb financi posit
factor compani rais cash beyond
result larg line prvb report net loss
per share versu estim per
share differ due slightli higher project oper
expens vs project nevertheless consid
larg line manag guid oper expens
cash runway prvb finish cash
cash equival subsequ receiv addit
op exercis warrant per
warrant prvb also file shelf registr includ
establish at-the-market atm agreement exclud non-
dilut project prvb receiv janssen decis
recal project cash burn per quarter
end indic prvb suffici cash reach
earli janssen recal payment would extend
runway late addit mp pledg
direct equiti invest next time prvb rais capit
includ janssen payment exclud atm piec
place prvb like access capit need see
teplizumab launch project
updat note note origin publish updat
warrant mischaracter issu
cash transact warrant howev issu cashless
exchang effect chang prvb cash remov
origin project receiv thu cash runway prvb
forecast earli price remain unchang
sotp analysi discount
rate termin growth rate
year price history/av daili volume mil prvb
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
assign provent share outperform rate price target prvb
maxim valu re-engag develop drug sidelin due
clinic failur caus poor trial design
target wrong diseas
prvb leverag partnership build ambiti portfolio focus prevent
delay autoimmun inflammatori diseas onset
experienc leadership team direct prior experi sever asset
revenu project
sum-of-the-part analysi wacc calcul discount rate termin
growth rate appli
sum-of-the-part analysi arriv price target per share
 cost consid part oper
asset valuat adjust probabl receiv regulatori approv base
strateg risk prvb greatest risk lie compani size rel portfolio size
decis maintain streamlin oper strategi help extend cash runway
also make execut clinic trial difficult may result failur achiev target
mileston timelin
financ risk abil rais addit fund crucial continu development
cours across compani pipelin inabl rais suffici fund need may result
program triag offload asset abil rais suffici capit may difficult
due higher need fund pipelin prvb size stage develop
licens risk call back provis relat prvb
licens agreement janssen respect factor impact
activ call back provis would valuat prvb full
impact truli account within valuat methodolog without project potenti
date and/or probabl provis activ
regulatori risk teplizumab prvb engag fda seek expedit
approv teplizumab patient risk type diabet outcom time fda
decis impact precis launch valuat teplizumab
good sold
research develop expens
gener administr expens
sale market
profit loss oper
chang fair valu warrant liabil
total incom expens
loss oper tax
accret seri convert redeem prefer stock
net loss attribut common stockhold
good sold
research develop expens
gener administr expens
sale market
profit loss oper
chang fair valu warrant liabil
total incom expens
loss oper tax
accret seri convert redeem prefer stock
net loss attribut common stockhold
growth profit ratio
cash equival
prepaid expens current asset
properti plant equip
total liabil stockhold equiti deficit
outstand share end period thousand
select metric thousand except per share
work capit thousand
cash equival market secur
cash equival
prepaid expens current asset
properti plant equip
total liabil stockhold equiti deficit
outstand share end period thousand
select metric thousand except per share
work capit thousand
cash equival market secur
flow oper activ
reconcili net loss net cash
stock-bas consider connect acquisit product
chang fair valu warrant liabil
increas decreas oper asset liabil
increas inventori
increas receiv
prepaid expens current asset
net cash provid use oper activ
flow invest activ
purchas properti plant equip
net cash provid use invest activ
flow financ activ
proce initi public offer net
proce issuanc seri convert redeem prefer
proce exercis warrant stock option
proce issuanc common stock
net cash provid financ activ
net increas decreas cash cash equival
cash equival begin period
cash equival end period
burn cash use opex
annual cash burn annual
year cash remain
month cash remain
flow oper activ
reconcili net loss net cash
stock-bas consider connect acquisit product
chang fair valu warrant liabil
increas decreas oper asset liabil
increas inventori
increas receiv
prepaid expens current asset
net cash provid use oper activ
flow invest activ
purchas properti plant equip
net cash provid use invest activ
flow financ activ
proce initi public offer net
proce issuanc seri convert redeem prefer
proce exercis warrant stock option
proce issuanc common stock
net cash provid financ activ
net increas decreas cash cash equival
cash equival begin period
cash equival end period
burn cash use opex
annual cash burn annual
year cash remain
month cash remain
